All In Biotech

Drug Trial Radar · NCT06546995

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

A Phase 1b, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Jul 9, 2024

Primary completion

Nov 19, 2025

Study completion Nov 19, 2025

Sponsor

Lead sponsor
Neumora Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment. Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Conditions

  • Alzheimer's Disease
  • Healthy Elderly

Interventions

  • NMRA-323511Drug

    Participants will receive NMRA-323511 orally.

  • PlaceboDrug

    Participants will receive matching placebo tablets orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events (TEAEs) and Validated Clinical ScalesTime frame: Up to 53 days
  2. Part B: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events and Validated Clinical ScalesTime frame: Up to Week 10
  3. Part B: Change from Baseline to Week 8 on the Cohen-Mansfield Agitation Inventory (CMAI) Total ScoreTime frame: Baseline to Week 8

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Neumora Investigator Site

    Chandler, Arizona

  • Neumora Investigator Site

    Tempe, Arizona

  • Neumora Investigator Site

    Costa Mesa, California

  • Neumora Investigator Site

    Lomita, California

  • Neumora Investigator Site

    Walnut Creek, California

  • Neumora Investigator Site

    Bradenton, Florida

  • Neumora Investigator Site

    Greenacres City, Florida

  • Neumora Investigator Site

    Hallandale, Florida

  • Neumora Investigator Site

    Hialeah, Florida

  • Neumora Investigator Site

    Miami, Florida

  • Neumora Investigator Site

    Miami, Florida

  • Neumora Investigator Site

    Miami, Florida

  • Neumora Investigator Site

    Miami Springs, Florida

  • Neumora Investigator Site

    Orlando, Florida

  • Neumora Investigator Site

    Pembroke Pines, Florida

  • Neumora Investigator Site

    Port Orange, Florida

  • Neumora Investigator Site

    Atlanta, Georgia

  • Neumora Investigator Site

    Honolulu, Hawaii

  • Neumora Investigator Site

    Boise, Idaho

  • Neumora Investigator Site

    Belmont, Massachusetts

  • Neumora Investigator Site

    Troy, Michigan

  • Neumora Investigator Site

    Toms River, New Jersey

  • Neumora Investigator Site

    Brooklyn, New York

  • Neumora Investigator Site

    East Syracuse, New York

  • Neumora Investigator Site

    Charlotte, North Carolina

  • Neumora Investigator Site

    Mesquite, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.